Syapse is a technology company.
N-Power Medicine is dedicated to transforming oncology drug development and clinical research culture through innovation, technology, and partnerships.
Syapse has raised $221.0M across 8 funding rounds.
Syapse has raised $221.0M in total across 8 funding rounds.
Syapse is a precision medicine technology company that builds a platform integrating real-world oncology data from electronic health records and genomics to deliver actionable patient insights, primarily serving healthcare organizations, providers, and community health systems to improve cancer care outcomes.[1][2][3][5] Its core products, such as Syapse Oncology, Syapse MDx, and Syapse PGx, provide end-to-end solutions for NGS-based diagnostics, from sample processing to physician reports, enabling data collaboration across networks of over 1,000 oncologists and nearly 300 hospitals managing about 10% of U.S. cancer cases.[1][2][3] The company raised $204.5M before its acquisition by N-Power Medicine in December 2024, which expanded N-Power's AI-enabled clinical research network for oncology trials and community-based care.[2][4]
Founded in 2008 and headquartered in San Francisco, California, Syapse (formerly BDLicense) emerged to address silos in oncology data by integrating electronic health records with genomic information for precision medicine.[1][2][3] Key early traction came from partnerships with major pharma like Roche (starting around 2018), Amgen, and Pfizer, which funded software development for measuring real-world evidence and scaling personalized oncology across health systems.[1][3] Pivotal moments included building a network spanning 25 states and collaborations that positioned it as a leader in real-world data analytics, culminating in its 2024 acquisition by N-Power Medicine to enhance community oncology research.[2][3][4]
Syapse rides the precision medicine trend, leveraging real-world evidence (RWE) from vast oncology datasets to bridge gaps in clinical trials and personalized treatments amid rising NGS adoption and AI-driven healthcare analytics.[2][3][5] Timing aligns with market forces like pharma's push for faster drug development—evidenced by Roche's long-term partnership—and the shift toward community-based care, where 85% of U.S. cancer patients receive treatment but face trial access barriers.[3][4] It influences the ecosystem by enabling health systems to scale precision oncology, fostering data collaboration that accelerates therapies and outcomes, now amplified through N-Power's "always-on" research model.[2][4]
Post-2024 acquisition, Syapse's platform will fuel N-Power's expansion of AI-enhanced clinical trials in community settings, potentially increasing trial participation and bringing therapies to millions faster.[2][4] Trends like AI integration in RWE and regulatory emphasis on real-world data will shape its path, evolving its influence from insights provider to core enabler of oncology innovation ecosystems.[3][4] As community networks grow, expect broader impact on reducing cancer burdens through scalable, data-driven care—tying back to its mission of transforming evidence into real-world patient experiences.[1][5]
Syapse has raised $221.0M in total across 8 funding rounds.
Syapse's investors include Esplanade HealthTech Ventures, Flybridge, Founders Fund, Insight Partners, Northpond Ventures, Presight Capital, Social Capital, Vensana Capital, Joanne Bradford, Nirav Tolia, Will Szczerbiak, Active Capital.
Syapse has raised $221.0M across 8 funding rounds. Most recently, it raised $35.0M Venture Round in July 2022.